Devyser, a pioneer in advanced genetic testing solutions, proudly announces the global launch of Devyser HLA Loss, a next-generation sequencing (NGS) assay designed exclusively to empower researchers with unprecedented sensitivity and speed in detecting HLA loss in post-transplantation studies. 

With immune escape becoming an increasingly important area of investigation in hematopoietic stem cell transplantation (HSCT) research, Devyser HLA Loss sets a new standard by offering precise, fast, and simple detection of HLA loss in mismatched transplant settings. 

Devyser HLA Loss is engineered for sensitive and accurate detection of HLA loss. Designed to complement existing chimerism assays, Devyser HLA Loss supports laboratories in building a comprehensive understanding of post-transplant immune dynamics. 

Addressing a critical gap in transplantation research 
HLA loss is a known mechanism of relapse in certain mismatched transplant scenarios. However, conventional tools may fall short in detecting such events at low levels. Devyser HLA Loss bridges this gap with precision, providing researchers with a reliable method to study immune escape mechanisms and potential treatment resistance patterns. 

"Our goal with Devyser HLA Loss is to bring unmatched sensitivity and ease-of-use to the research community. This launch marks a significant step forward in enabling translational research that could influence future diagnostic and therapeutic strategies,” said Theis Kipling, CCO, Devyser. 

Devyser HLA Loss is currently available globally as a Research Use Only (RUO) product. For product details, visit: https://devyser.com/kits-and-reagents/devyser-hla-loss.